Wed, Apr 23, 2014, 11:07 AM EDT - U.S. Markets close in 4 hrs 53 mins

Recent

% | $
Quotes you view appear here for quick access.

Muscle Pharm Corp. Message Board

  • fkk_kass fkk_kass Dec 30, 2013 10:27 AM Flag

    Seeking answers / opinions / guesses / speculation about Arnold line sales...

    Arnold launched at the beginning of Q4. In the Q3 conference call held on Nov 15th, there was a fair amount of discussion about Arnold sales for the first two months ($3.7M, if I remember correctly). Did MSLP ever give any idea about what portion of that - if any - was reflected in Q3 sales figures? They obviously have to ship product to brick and mortar stores in advance, but I have no idea how much lead time is required or any knowledge of when sales revenue is recognized.

    Is it likely / certain that some portion of that $3.7M was reflected in Q3 sales? If not, one would obviously expect a huge increase in Q4 sales.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think you are on the right track - and thanks for making another worthy topic (not this trash stuff others post).
      ARNOLD will see a big increase in Q4 for just that reason. I have a feeling a majority of that was online sales, since that's easily documentable. As for the brink and mortar stores, its a lot harder to judge sales on a daily/weekly basis. But I also don't know much about that aspect of sales.
      I think ARNOLD will just add to revs, but will cannibalize their other products. However, if I remember right, margins are better for ARNOLD - so that may not be half bad. EIther way, people are buying MSLP prodcuts, so whether is ARNOLD or their original line, the $$ all spends the same.

      • 1 Reply to mtc44380
      • Thanks mtc. Who knows when the SEC will be resolved, or what the resolution will be. But it WILL be resolved - hopefully soon, certainly eventually. While it obviously would have been better for the investigation never to have occurred, the fact that the investigation is still outstanding is actually a GOOD thing for those who are still accumulating shares. There is going to be - eventually - a MASSIVE increase in share price. The ongoing fact of the investigation is depressing the share price. It's eventual resolution - REGARDLESS OF THE OUTCOME - will almost certainly trigger a strong increase in share price. Meanwhile, every other forseeable event is hugely favorable. The company is supposed to provide 2014 guidance in a few weeks. I expect the figures they project to be stunningly good. Walgeens is just around the corner - possibly tomorrow! Q4 numbers should be available near the end of February, and should be excellent. Uplisting will likely come soon after conclusion of the SEC investigation, whenever that is. I expect them to annouce some sort of relationship with an investment banker soon - including a line of credit that will hopefully preclude any future dilution until the share price is MUCH higher.

        I see today's announcement as a very good thing. There is no doubt in my mind that they are taking all the right steps towards building a "real" company, and moving away from their admittedly shady origins. My only real complaints center around:

        a) Management's propensity to throw money at itself too freely and too early. Post some clean, strong earnings for a qtr or two and the share price will SOAR! Then hand out rich bonues and shares of stock that are really WORTH something.
        b) Management's propensity - due to Dr. Frost's influence, no doubt - to act as if MSLP were a pharma company. I think these BZNE / FUSE investments are "make a killing or lose it all" type investments that are not appropriate for this company at this time.

 
MSLP
7.00-0.21(-2.91%)10:42 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.